About Erin Newburn, MS, PhD

Erin joined Personalis as a Field Application Scientist in 2013 with research experience in the areas of molecular biology, genetics, and biotechnology.  As the Senior Field Applications Manager, Erin’s team has global responsibility for providing both pre and post-sale technical support for the Personalis ACE Cancer Portfolio. She completed her postdoctoral training at the National Institute of Mental Health (NIMH) investigating candidate susceptibility genes for major psychiatric illnesses. Erin received her Ph.D. from the Ohio State University in Integrated Biomedical Science as a Presidential Fellow.
11 May, 2022

How Liquid Biopsy Technology is Changing What’s Possible in Cancer Treatment

Erin Newburn, MS, PhD Sr. Director, Field Applications Scientist How Liquid Biopsy Technology is Changing What's Possible in Cancer Treatment There’s no doubt that early detection is essential for good outcomes when dealing with cancer treatment, and this is equally true when detecting disease recurrence. Patients who have already undergone [...]

29 Jun, 2021

Leveraging RNA Sequencing Data in Predicting Immunotherapy Response

Erin Newburn, MS, PhD Sr. Director, Field Application Scientist Leveraging RNA Sequencing Data in Predicting Immunotherapy Response Can transcriptomics help us fine tune tumor specific responses and transform personalization of therapy? The complexity of understanding immune checkpoint blockade response has been abundantly documented in recent studies. Also increasingly studied is [...]

23 Jul, 2018

Five unanswered questions regarding personalized neoantigen cancer vaccines

Erin Newburn, MS, PhD Associate Director, Field Applications Scientist Five unanswered questions regarding personalized neoantigen cancer vaccines  From data presented at both AACR and ASCO in the past months, amazing progress continues to be made in the development of neoantigen vaccines.  As we marvel at the growth and big steps [...]

5 Mar, 2018

Understanding the role of HLA in Cancer Immunotherapy

Erin Newburn, MS, PhD Associate Director, Field Applications Scientist Understanding the role of Human Leukocyte Antigen in Cancer Immunotherapy The Flagpole MHC (major histocompatibility complex), also known as HLA (human leukocyte antigen) is the entire set of genes that code for proteins involved in antigen presentation.  Very simply, you could [...]

29 Nov, 2017

Ethnic disparities in precision genomics

The premise of the right drug for the right patient at the right time is critical for indications from cardiovascular and infectious disease to the latest immuno-oncology strategies.  It’s imperative to comprehend which patient will derive benefit from ...

Go to Top